|
1
|
Bottos A and Hynes NE: Cancer: Staying
together on the road to metastasis. Nature. 514:309–310. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xuan Q, Ji H, Tao X, Xu Y and Zhang Q:
Quantitative assessment of HER2 amplification in HER2-positive
breast cancer: Its association with clinical outcomes. Breast
Cancer Res Treat. 150:581–588. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang Y, Zhang Y, Pan C, Ma F and Zhang S:
Prediction of poor prognosis in breast cancer patients based on
microRNA-21 expression: A meta-analysis. PLoS One. 10:e01186472015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grobosch T, Schwarze B, Stoecklein D and
Binscheck T: Fatal poisoning with Taxus baccata: Quantification of
paclitaxel (taxol A), 10-deacetyltaxol, baccatin III,
10-deacetylbaccatin III, cephalomannine (taxol B), and
3,5-dimethoxyphenol in body fluids by liquid chromatography-tandem
mass spectrometry. J Anal Toxicol. 36:36–43. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Johnson MT, Reichley R, Hoppe-Bauer J,
Dunne WM, Micek S and Kollef M: Impact of previous antibiotic
therapy on outcome of Gram-negative severe sepsis. Crit Care Med.
39:1859–1865. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ganoth A, Merimi KC and Peer D: Overcoming
multidrug resistance with nanomedicines. Expert Opin Drug Deliv.
12:223–238. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ohashi-Kobayashi A, Ohashi K, Du WB, Omote
H, Nakamoto R, Al-Shawi M and Maeda M: Examination of drug
resistance activity of human TAP-like (ABCB9) expressed in yeast.
Biochem Biophys Res Commun. 343:597–601. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kaur P, Garg T, Rath G, Murthy RS and
Goyal AK: Development, optimization and evaluation of
surfactant-based pulmonary nanolipid carrier system of paclitaxel
for the management of drug resistance lung cancer using Box-Behnken
design. Drug Deliv. 23:1912–1925. 2016.PubMed/NCBI
|
|
9
|
Zhu Z, Mu Y, Qi C, Wang J, Xi G, Guo J, Mi
R and Zhao F: CYP1B1 enhances the resistance of epithelial ovarian
cancer cells to paclitaxel in vivo and in vitro. Int J Mol Med.
35:340–348. 2015.PubMed/NCBI
|
|
10
|
Verma K and Ramanathan K: Investigation of
paclitaxel resistant R306C mutation in β-tubulin-a computational
approach. J Cell Biochem. 116:1318–1324. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Png KJ, Halberg N, Yoshida M and Tavazoie
SF: A microRNA regulon that mediates endothelial recruitment and
metastasis by cancer cells. Nature. 481:190–194. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shibayama Y, Kondo T, Ohya H, Fujisawa SI,
Teshima T and Iseki K: Upregulation of microRNA-126-5p is
associated with drug resistance to cytarabine and poor prognosis in
AML patients. Oncol Rep. 33:2176–2182. 2015.PubMed/NCBI
|
|
13
|
Acunzo M, Romano G, Wernicke D and Croce
CM: MicroRNA and cancer-a brief overview. Adv Biol Regul. 57:1–9.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu PN, Yan MD, Lai HC, Huang RL, Chou YC,
Lin WC, Yeh LT and Lin YW: Downregulation of miR-29 contributes to
cisplatin resistance of ovarian cancer cells. Int J Cancer.
134:542–551. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Y, Duan G and Feng S: MicroRNA-301a
modulates doxorubicin resistance in osteosarcoma cells by targeting
AMP-activated protein kinase alpha 1. Biochem Biophys Res Commun.
459:367–373. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chatterjee A, Chattopadhyay D and
Chakrabarti G: miR-17-5p downregulation contributes to paclitaxel
resistance of lung cancer cells through altering beclin1
expression. PLoS One. 9:e957162014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gao Y, Liu Y, Du L, Li J, Qu A, Zhang X,
Wang L and Wang C: Downregulation of miR-24-3p in colorectal cancer
is associated with malignant behavior. Med Oncol. 32:3622015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guo C, Deng Y, Liu J and Qian L:
Cardiomyocyte-specific role of miR-24 in promoting cell survival. J
Cell Mol Med. 19:103–112. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang T, Sun P, Chen L, Huang Q, Chen K,
Jia Q, Li Y and Wang H: Cinnamtannin D-1 protects pancreatic
β-cells from palmitic acid-induced apoptosis by attenuating
oxidative stress. J Agric Food Chem. 62:5038–5045. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu J, Sun P, Zhang X, Liu H, Jiang H, Zhu
W and Wang H: Inhibition of GPR40 protects MIN6 β cells from
palmitate- induced ER stress and apoptosis. J Cell Biochem.
113:1152–1158. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang XW, Xi XQ, Wu J, Wan YY, Hui HX and
Cao XF: microRNA-206 attenuates tumor proliferation and migration
involving the downregulation of NOTCH3 in colorectal cancer. Oncol
Rep. 33:1402–1410. 2015.PubMed/NCBI
|
|
22
|
Huang J, Li H and Ren G:
Epithelial-mesenchymal transition and drug resistance in breast
cancer (Review). Int J Oncol. 47:840–848. 2015.PubMed/NCBI
|
|
23
|
Lin SC, Liu CJ, Lin JA, Chiang WF, Hung PS
and Chang KW: miR-24 up-regulation in oral carcinoma: Positive
association from clinical and in vitro analysis. Oral Oncol.
46:204–208. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qin W, Shi Y, Zhao B, Yao C, Jin L, Ma J
and Jin Y: miR-24 regulates apoptosis by targeting the open reading
frame (ORF) region of FAF1 in cancer cells. PLoS One. 5:e94292010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao G, Liu L, Zhao T, Jin S, Jiang S, Cao
S, Han J, Xin Y, Dong Q, Liu X and Cui J: Upregulation of miR-24
promotes cell proliferation by targeting NAIF1 in non-small cell
lung cancer. Tumour Biol. 36:3693–3701. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu YX, Long XD, Xi ZF, Ma Y, Huang XY,
Yao JG, Wang C, Xing TY and Xia Q: MicroRNA-24 modulates aflatoxin
B1-related hepatocellular carcinoma prognosis and tumorigenesis.
Biomed Res Int. 2014:4829262014.PubMed/NCBI
|
|
27
|
Duan Y, Hu L, Liu B, Yu B, Li J, Yan M, Yu
Y, Li C, Su L, Zhu Z, et al: Tumor suppressor miR-24 restrains
gastric cancer progression by downregulating RegIV. Mol Cancer.
13:1272014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu J, Zhang YC, Suo WH, Liu XB, Shen WW,
Tian H and Fu GH: Induction of anion exchanger-1 translation and
its opposite roles in the carcinogenesis of gastric cancer cells
and differentiation of K562 cells. Oncogene. 29:1987–1996. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mishra PJ, Song B, Mishra PJ, Wang Y,
Humeniuk R, Banerjee D, Merlino G, Ju J and Bertino JR: MiR-24
tumor suppressor activity is regulated independent of p53 and
through a target site polymorphism. PLoS One. 4:e84452009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sochor M, Basova P, Pesta M, Dusilkova N,
Bartos J, Burda P, Pospisil V and Stopka T: Oncogenic microRNAs:
miR-155, miR-19a, miR-181b and miR-24 enable monitoring of early
breast cancer in serum. BMC Cancer. 14:4482014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yin JY, Deng ZQ, Liu FQ, Qian J, Lin J,
Tang Q, Wen XM, Zhou JD, Zhang YY and Zhu XW: Association between
mir-24 and mir-378 in formalin-fixed paraffin-embedded tissues of
breast cancer. Int J Clin Exp Pathol. 7:4261–4267. 2014.PubMed/NCBI
|
|
32
|
Du WW, Fang L, Li M, Yang X, Liang Y, Peng
C, Qian W, O'Malley YQ, Askeland RW, Sugg SL, et al: MicroRNA
miR-24 enhances tumor invasion and metastasis by targeting PTPN9
and PTPRF to promote EGF signaling. J Cell Sci. 126:1440–1453.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Demirel O, Bangert I, Tampé R and Abele R:
Tuning the cellular trafficking of the lysosomal peptide
transporter TAPL by its N-terminal domain. Traffic. 11:383–393.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hlavata I, Mohelnikova-Duchonova B,
Vaclavikova R, Liska V, Pitule P, Novak P, Bruha J, Vycital O,
Holubec L, Treska V, et al: The role of ABC transporters in
progression and clinical outcome of colorectal cancer. Mutagenesis.
27:187–196. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu F, Wang F, Yang T, Sheng Y, Zhong T and
Chen Y: Differential drug resistance acquisition to doxorubicin and
paclitaxel in breast cancer cells. Cancer Cell Int. 14:5382014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dong Z, Zhong Z, Yang L, Wang S and Gong
Z: MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small
cell lung cancer cells by regulating the drug transporter ABCB9.
Cancer Lett. 343:249–257. 2014. View Article : Google Scholar : PubMed/NCBI
|
